MedTrace Logo

Bipolar Androgen Therapy + Carboplatin in mCRPC

NCT03522064 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-23

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy of BAT and carboplatin in men with metastatic castrate-resistant prostate cancer (mCRPC).

Conditions

  • Castration-resistant Prostate Cancer
  • Homologous Recombination Deficiency

Interventions

DRUG

Testosterone Enanthate 100 MG/ML Injectable Solution

Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL.

DRUG

Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5

Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL. Carboplatin as per standard procedures

Sponsors & Collaborators

  • St Vincent's Hospital, Sydney

    lead OTHER

Principal Investigators

  • Anthony M Joshua, MBBS, PhD, FRACP · St Vincent's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-30
Primary Completion
2026-09-30
Completion
2027-12-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03522064 on ClinicalTrials.gov